Fear reduction in patients with chronic pain: a learning theory perspective.

Abstract:

:Acute pain informs the individual that there is an imminent threat of body damage, and is associated with the urge to escape and avoid. Fear learning takes place when neutral stimuli receive the propensity to predict the occurrence of pain, and when defensive responses are initiated in anticipation of potential threats to the integrity of the body. Fear-avoidance models have been put forward featuring the role of individual differences in catastrophic interpretations of pain in the modulation of learning and avoidance. Based on extensive literature on fear reduction in anxiety disorders; cognitive-behavioral treatments have been developed and applied to patients with chronic pain reporting substantial pain-related fear. In this article, we discuss mechanisms underlying the acquisition, the assessment and extinction of pain-related fear through the cognitive-behavioral treatment of pain-related fear. Finally, we provide a number of critical notes and directions for future research in the field of chronic pain and pain-related fear.

journal_name

Expert Rev Neurother

authors

den Hollander M,de Jong JR,Volders S,Goossens ME,Smeets RJ,Vlaeyen JW

doi

10.1586/ern.10.115

subject

Has Abstract

pub_date

2010-11-01 00:00:00

pages

1733-45

issue

11

eissn

1473-7175

issn

1744-8360

journal_volume

10

pub_type

杂志文章,评审
  • Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?

    abstract::Evaluation of: Segal BM, Constantinescu CS, Raychaudhuri A et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a Phase II, double-blind, placebo-controlled, randomized, dose-ranging study. Lancet Neurol. 7, 796-804 (2008). ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.9.3.319

    authors: Longbrake EE,Racke MK

    更新日期:2009-03-01 00:00:00

  • Pharmacotherapy for social anxiety disorder: a systematic review.

    abstract::Social anxiety disorder (SAD) is a prevalent, disabling disorder. We aimed to assess the effects of pharmacotherapy for SAD and to determine whether particular classes of medication are more effective and/or better tolerated than others. A systematic review and meta-analysis was conducted of all published and unpublis...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.2.235

    authors: Ipser JC,Kariuki CM,Stein DJ

    更新日期:2008-02-01 00:00:00

  • Cognitive changes in multiple sclerosis.

    abstract::Cognitive dysfunction (CD) affects 40-65% of multiple sclerosis (MS) patients and can have a great functional impact. It can be detected in all the disease phenotypes from the early stages of the disease and tends to progress over time. Memory, complex attention, information processing speed and executive functions ar...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.10.1585

    authors: Amato MP,Zipoli V,Portaccio E

    更新日期:2008-10-01 00:00:00

  • Cladribine for multiple sclerosis: review and current status.

    abstract::In the 1990s, cladribine was developed as an adenosine deaminase-resistant nucleoside analog with selective lymphotoxic specificity in the hope that it might become useful in the treatment of some lymphoid neoplasms and autoimmune disorders. Several clinical trials demonstrated very significant effectiveness and safet...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.6.721

    authors: Sipe JC

    更新日期:2005-11-01 00:00:00

  • Highlights in muscle relaxants.

    abstract::The aim of this article is to provide an overview on neuromuscular blocking agents and a rational selection of the most appropriate agents, along with pharmacological and pharmacoeconomic considerations on neuromuscular blockers and their antagonists. Neuromuscular blocking agents are used during anesthesia to facilit...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.12.1833

    authors: Leykin Y,Pellis T,Vincenti E

    更新日期:2006-12-01 00:00:00

  • An update on the recognition and treatment of non-convulsive status epilepticus in the intensive care unit.

    abstract:INTRODUCTION:Non-convulsive status epilepticus (NCSE) is a complex and diverse condition which is often an under-recognised entity in the intensive care unit. When NCSE is identified the optimal treatment strategy is not always clear. Areas covered: This review is based on a literature review of the key literature in t...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1369880

    authors: Kinney MO,Kaplan PW

    更新日期:2017-10-01 00:00:00

  • Evaluation and management of headache in primary care.

    abstract::Headache disorders are ubiquitous, common, disabling and to a very large extent treatable in primary care. In this review, the important headache disorders are described together with their impact on public health. Suggestions are set out for their optimal management, although many of these are necessarily based more ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.4.3.425

    authors: Steiner TJ

    更新日期:2004-05-01 00:00:00

  • Cannabidiol as potential treatment in refractory pediatric epilepsy.

    abstract::In recent years there has been great scientific and public interest focused on the therapeutic potential of compounds derived from cannabis for the treatment of refractory epilepsy in children. From in vitro and in vivo studies on animal models, cannabidiol (CBD) appears to be a promising anticonvulsant drug with a fa...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2016.1121098

    authors: Paolino MC,Ferretti A,Papetti L,Villa MP,Parisi P

    更新日期:2016-01-01 00:00:00

  • Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.

    abstract::Neuroprotective therapy has been proposed for age-related neurodegenerative disorders, including Parkinson's disease. Inhibitors of type B monoamine oxidase (MAOB-Is), rasagiline and (-)deprenyl, are the most promising candidate neuroprotective drugs. Clinical trials of rasagiline in patients with Parkinson's disease ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/ern.09.68

    authors: Naoi M,Maruyama W

    更新日期:2009-08-01 00:00:00

  • Current concept of anxiety: implications from Darwin to the DSM-V for the diagnosis of generalized anxiety disorder.

    abstract::This article proposes a revision of the historical evolution of the concepts of generalized anxiety disorder (GAD). Currently, Darwin's evolutionary theory is the hegemonic paradigm for modern science and influences research on mental disorders. Throughout the 20th Century, the editions of the Diagnostic and Statistic...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.101

    authors: Coutinho FC,Dias GP,do Nascimento Bevilaqua MC,Gardino PF,Pimentel Rangé B,Nardi AE

    更新日期:2010-08-01 00:00:00

  • Nusinersen for the treatment of spinal muscular atrophy.

    abstract:INTRODUCTION:Spinal muscular atrophy (SMA) is an autosomal recessive degenerative neuromuscular disorder characterized by loss of spinal motor neurons leading to muscle weakness. This review article focuses on a novel antisense oligonucleotide treatment, first ever approved for SMA (nusinersen, SpinrazaTM) and describe...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1364159

    authors: Chiriboga CA

    更新日期:2017-10-01 00:00:00

  • Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?

    abstract::Braak's proposal that, in patients with Parkinson's disease, Lewy bodies and neurites progressively invade the brain through regions connected to autonomic and olfactory centers remains contentious. Confounding factors include the lack of an in vivo marker to examine the progression of Lewy pathology, the retrospectiv...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.47

    authors: Halliday G,McCann H,Shepherd C

    更新日期:2012-06-01 00:00:00

  • Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis.

    abstract::Glucocorticoids exert a variety of immunomodulatory activities. Since changes in glucocorticoid homeostasis impact on susceptibility to autoimmune diseases, and synthetic glucocorticoids are widely used in the treatment of multiple sclerosis, a detailed understanding of their mechanism of action is desirable. Experime...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.11.1657

    authors: Reichardt HM,Gold R,Lühder F

    更新日期:2006-11-01 00:00:00

  • Trigeminal neuralgia and persistent idiopathic facial pain.

    abstract::Trigeminal neuralgia (TN) and persistent idiopathic facial pain (PIFP) are two of the most puzzling orofacial pain conditions and affected patients are often very difficult to treat. TN is characterized by paroxysms of brief but severe pain followed by asymptomatic periods without pain. In some patients a constant dul...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.156

    authors: Obermann M,Holle D,Katsarava Z

    更新日期:2011-11-01 00:00:00

  • Microbiota-gut brain axis involvement in neuropsychiatric disorders.

    abstract::Introduction: The microbiota-gut brain (MGB) axis is the bidirectional communication between the intestinal microbiota and the brain. An increasing body of preclinical and clinical evidence has revealed that the gut microbial ecosystem can affect neuropsychiatric health. However, there is still a need of further studi...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1638763

    authors: Iannone LF,Preda A,Blottière HM,Clarke G,Albani D,Belcastro V,Carotenuto M,Cattaneo A,Citraro R,Ferraris C,Ronchi F,Luongo G,Santocchi E,Guiducci L,Baldelli P,Iannetti P,Pedersen S,Petretto A,Provasi S,Selmer K,Sp

    更新日期:2019-10-01 00:00:00

  • Broad spectrum micronutrient formulas for the treatment of symptoms of depression, stress, and/or anxiety: a systematic review.

    abstract::Introduction: Vitamin and mineral nutritional supplements are becoming increasingly popular as alternative treatments for anxiety and depression, as issues such as side effects from medication, failure to respond to psychotherapy and workforce limitations pose barriers for successful treatment.Areas covered: This revi...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1740595

    authors: Blampied M,Bell C,Gilbert C,Rucklidge JJ

    更新日期:2020-04-01 00:00:00

  • Zonisamide: newer antiepileptic agent with multiple mechanisms of action.

    abstract::Zonisamide (Zonegran, Eisai, Inc.) is a broad spectrum antiepileptic drug indicated for use as adjunctive therapy in the treatment of partial seizures. Zonisamide has multiple mechanisms of action, which may explain widespread reports of its utility in focal epilepsy and generalized epilepsy, and for nonseizure disord...

    journal_title:Expert review of neurotherapeutics

    pub_type: 历史文章,杂志文章,评审

    doi:10.1586/14737175.4.6.935

    authors: Biton V

    更新日期:2004-11-01 00:00:00

  • The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder.

    abstract::Pharmacotherapy, psychotherapy and other nonpharmacological interventions are used in patients with major depressive disorder (MDD). However, 50% of the patients with MDD fail to achieve a response to first-line antidepressant treatment. In four of five acute monotherapy studies, once-daily extended-release quetiapine...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2013.846520

    authors: Weisler R,McIntyre RS

    更新日期:2013-11-01 00:00:00

  • The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease.

    abstract:INTRODUCTION:Antipsychotics have long been the mainstay of treatment for agitation and psychosis in Alzheimer's disease. Despite their current use successive studies have shown that they only confer a modest benefit which must be balanced against their well-established serious side effects (extrapyramidal symptoms, str...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2018.1476140

    authors: Creese B,Da Silva MV,Johar I,Ballard C

    更新日期:2018-06-01 00:00:00

  • Stem cell therapy for Parkinson's disease.

    abstract::The aim of stem cell therapy for Parkinson's disease is to reconstruct nigro-striatal neuronal pathways using endogenous neural stem/precursor cells or grafted dopaminergic neurons. As an alternative, transplantation of stem cell-derived dopaminergic neurons into the striatum has been attempted, with the aim of stimul...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.6.667

    authors: Takahashi J

    更新日期:2007-06-01 00:00:00

  • Craniomandibular muscles, intraoral orthoses and migraine.

    abstract::Intraoral splints are effective in migraine prevention. In this review, changes in the quality of life of migraineurs treated with a palatal nonoccluding splint were measured. Using the Migraine Specific Quality of Life Instrument (Version 2.1), it was found that the palatal nonoccluding splint significantly improved ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.3.371

    authors: Shevel E

    更新日期:2005-05-01 00:00:00

  • Sumatriptan needle-free subcutaneous (Sumavel(®) DosePro™) approved for the acute treatment of migraine, with or without aura, and cluster headaches.

    abstract::Sumatriptan subcutaneous administration is the fastest and most effective of the triptans for relief of acute migraine headache. This occurs even when the patient has already developed symptoms related to central sensitization, a key parameter in determining the effectiveness of these agents. In patients whose migrain...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.41

    authors: Freitag FG

    更新日期:2011-04-01 00:00:00

  • Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

    abstract::Median survival of patients with malignant glioma (MG) from time of diagnosis is approximately 1 year, despite surgery, irradiation and conventional chemotherapy. Improving patient outcome relies on our ability to develop more effective therapies that are directed against the unique molecular aberrations within a pati...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.116

    authors: Thaker NG,Pollack IF

    更新日期:2009-12-01 00:00:00

  • Fingolimod for the treatment of relapsing multiple sclerosis.

    abstract::Fingolimod is the first oral agent approved in the USA for the treatment of relapsing forms of multiple sclerosis. Fingolimod is a sphingosine 1-phosphate receptor modulator that binds to sphingosine 1-phosphate receptors on lymphocytes, resulting in a downregulation of the receptor and a reversible sequestration of l...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.193

    authors: Jeffery DR,Markowitz CE,Reder AT,Weinstock-Guttman B,Tobias K

    更新日期:2011-02-01 00:00:00

  • Repetitive transcranial magnetic stimulation as treatment for anxiety disorders.

    abstract::Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive and generally well-tolerated method of focally stimulating brain regions. It has been shown to be efficacious in the treatment for depression, but only to a limited degree. It has also been investigated for the treatment of some anxiety disorders, pa...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1586/14737175.8.10.1449

    authors: Pigot M,Loo C,Sachdev P

    更新日期:2008-10-01 00:00:00

  • Improving outcomes of subthalamic nucleus deep brain stimulation in Parkinson's disease.

    abstract::The subthalamic nucleus (STN) has been a major target of deep brain stimulation (DBS) for Parkinson's disease (PD) over the past 20 years. The benefits of DBS of the STN include: decreased motor fluctuations and bradykinesia, tremor reduction and a reduction in dopaminergic drug requirements and dyskinesias. Despite t...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1081815

    authors: Bari AA,Fasano A,Munhoz RP,Lozano AM

    更新日期:2015-10-01 00:00:00

  • Gene therapy applications for the treatment of neuropathic pain.

    abstract::Neuropathic pain is notoriously difficult to treat; currently available pharmaceutical drugs result in moderate analgesia in approximately a third of patients. As our understanding of the biological processes involved in the establishment and maintenance of neuropathic pain increases, so does the development of novel ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.5.487

    authors: Goss JR,Goins WF,Glorioso JC

    更新日期:2007-05-01 00:00:00

  • Fentanyl for breakthrough pain: a systematic review.

    abstract::The purpose of this article is to systematically review the use of fentanyl as an analgesic for breakthrough pain. This article found that the oral transmucosal fentanyl (OTFC) had a quicker onset to analgesia than oral immediate-release opioids. Intranasal fentanyl (INFS) had a quicker onset to analgesia than buccal ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.63

    authors: Davis MP

    更新日期:2011-08-01 00:00:00

  • What happens when natalizumab therapy is stopped?

    abstract::Natalizumab is an α-4 integrin antagonist used for the treatment of relapsing multiple sclerosis (MS). Concerns with the drug have a risen owing to a heightened risk of progressive multifocal leukoencephalopathy, which has caused some physicians to interrupt or stop treatment altogether. The article under review evalu...

    journal_title:Expert review of neurotherapeutics

    pub_type: 评论,杂志文章

    doi:10.1586/ern.11.109

    authors: Schaaf SM,Pitt D,Racke MK

    更新日期:2011-09-01 00:00:00

  • Genome-wide investigation of rare structural variants identifies VIPR2 as a new candidate gene for schizophrenia.

    abstract::Research has shown that structural variation in the human genome, including rare copy number variations (CNVs), contributes to genetic susceptibility to psychiatric diseases, such as schizophrenia, a devastating complex disorder with a high genetic load. The study by Vacic et al. applied a genome-wide approach to dete...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.84

    authors: Nieratschker V,Meyer-Lindenberg A,Witt SH

    更新日期:2011-07-01 00:00:00